Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab

OBJECTIVE: To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA). METHODS: Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA- and uv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanz, Sofia, Seidel, Gerald, Skrabl-Baumgartner, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380315/
https://www.ncbi.nlm.nih.gov/pubmed/34419092
http://dx.doi.org/10.1186/s12969-021-00630-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380315/
https://www.ncbi.nlm.nih.gov/pubmed/34419092
http://dx.doi.org/10.1186/s12969-021-00630-1

Ejemplares similares